These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8301579

  • 1. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.
    Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N.
    J Pharmacol Exp Ther; 1994 Jan; 268(1):380-7. PubMed ID: 8301579
    [Abstract] [Full Text] [Related]

  • 2. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.
    Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N.
    J Pharmacol Exp Ther; 1994 Aug; 270(2):822-30. PubMed ID: 8071874
    [Abstract] [Full Text] [Related]

  • 3. Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.
    Kindt MV, Heikkila RE, Nicklas WJ.
    J Pharmacol Exp Ther; 1987 Sep; 242(3):858-63. PubMed ID: 3498818
    [Abstract] [Full Text] [Related]

  • 4. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
    Giovanni A, Sonsalla PK, Heikkila RE.
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
    [Abstract] [Full Text] [Related]

  • 5. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
    Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK.
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
    [Abstract] [Full Text] [Related]

  • 6. Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate.
    Matarredona ER, Santiago M, Machado A, Cano J.
    Br J Pharmacol; 1997 Jul; 121(5):1038-44. PubMed ID: 9222565
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.
    Castagnoli N, Castagnoli KP, Van der Schyf CJ, Usuki E, Igarashi K, Steyn SJ, Riker RR.
    Pol J Pharmacol; 1999 Jul; 51(1):31-8. PubMed ID: 10389142
    [Abstract] [Full Text] [Related]

  • 16. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats.
    Ablordeppey SY, Borne RF.
    Pharmacol Biochem Behav; 1993 Nov; 46(3):739-44. PubMed ID: 8278454
    [Abstract] [Full Text] [Related]

  • 17. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
    Foster SB, Wrona MZ, Han J, Dryhurst G.
    Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.